Gilead Transfers Trodelvy Asian Rights to Everest Medicines for USD280m
US pharmaceutical major Gilead Sciences Inc. (NASDAQ: GILD) today announced an agreement with Everest Medicines...
ADC / XDC
Innovent Biologics and Sanofi Announce License Deal for Drug Development in China
China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have...
ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO
China-based macromolecular targeted therapy developer ProfoundBio (Suzhou) Co., Ltd announced that it has received clinical...
AstraZeneca’s H1 2022 Revenues Surge 48%, Led by Oncology and Vaccines
UK-based AstraZeneca (AZ, NASDAQ: AZN) released its financial report for H1 2022, showing a 48%...
Mabwell Bioscience Gets FDA Approval for Nectin-4 ADC 9MW2821 in Solid Tumors
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced it has received approval from the...
LaNova Medicines Gets FDA Green Light for LM-305 Myeloma Study
Shanghai-based cancer therapy developer LaNova Medicines Ltd announced it has received approval from the U.S....
Merck’s Q2 Sales Surge 31% to USD 14.6B, Led by Keytruda and China Growth
US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) reported Q2 2022 global sales of USD...
CSPC Jushi Biopharm’s SYSA1801 ADC Secures Licensing Deal with Elevation Oncology
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary, CSPC Jushi Biopharmaceutical Co.,...
Sichuan Kelun Pharmaceutical and Merck Sharp & Dohme Corp. Ink Second ADC Licensing Deal
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that US-based Merck Sharp & Dohme...
DAC Biotech’s DXC005 ADC Doses First Patient in Beijing Cancer Hospital Trial
China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing of its...
Sesen Bio Terminates Vicineum Development After FDA Talks, Citing Phase III Costs
Sesen Bio Inc. (NASDAQ: SESN) announced the termination of clinical development for Vicineum (VB4-845), its...
Kelun Pharma’s SKB264 ADC Receives NMPA Green Light for Phase II Solid Tumor Study
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that its antibody drug conjugate (ADC)...
Overland ADCT BioPharma Doses First Patient in Zynlonta’s Phase III LOTIS-5 Study for DLBCL
Overland ADCT BioPharma (CY) Ltd, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC...
Zhejiang Medicine’s ARX305 ADC Receives Clinical Trial Approval for CD70-Positive Cancers
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that its subsidiary NovoCodex Biopharmaceuticals Ltd has...
Overland ADCT BioPharma Launches Global Phase III Trial for Zynlonta in DLBCL
Overland ADCT BioPharma, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC Therapeutics SA...
Bio-Thera Solutions Doses First Patient in BAT8006 Phase I Study for Solid Tumors
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that the first patient has been dosed in a...
OBI Pharma Halts OBI 888 Trial Over Manufacturing Costs, Shifts Focus to Globo H ADC
Taiwan-based OBI Pharma (TPEx: 4174) announced the discontinuation of a Phase I/II trial for its...
Hangzhou DAC Bio Partners with Janssen on ADC Development Deal
China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a...
WuXi XDC Partners with AbTis to Advance ADC Development and Manufacturing
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (SHA: 603259),...
Bio-Thera Solutions’ BAT8010 Receives NMPA Approval for Solid Tumor Clinical Trials
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that it has received approval from the National Medical...